Bayesian probability of success for clinical trials using historical data

被引:24
作者
Ibrahim, Joseph G. [1 ]
Chen, Ming-Hui [2 ]
Lakshminarayanan, Mani [3 ]
Liu, Guanghan F. [4 ]
Heyse, Joseph F. [4 ]
机构
[1] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA
[2] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA
[3] Pfizer Inc, Biotechnol Clin Dev, Collegeville, PA 19426 USA
[4] Merck & Co Inc, Whitehouse Stn, NJ 08889 USA
关键词
average probability of success; fitting prior; linear regression; marginal likelihood; power prior; simulation; validation prior; REGRESSION-MODELS; SAMPLE-SIZE; IMMUNOGENICITY; MECHANISM; ZOSTAVAX; SAFETY;
D O I
10.1002/sim.6339
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Developing sophisticated statistical methods for go/no-go decisions is crucial for clinical trials, as planning phase III or phase IV trials is costly and time consuming. In this paper, we develop a novel Bayesian methodology for determining the probability of success of a treatment regimen on the basis of the current data of a given trial. We introduce a new criterion for calculating the probability of success that allows for inclusion of covariates as well as allowing for historical data based on the treatment regimen, and patient characteristics. A new class of prior distributions and covariate distributions is developed to achieve this goal. The methodology is quite general and can be used with univariate or multivariate continuous or discrete data, and it generalizes Chuang-Stein's work. This methodology will be invaluable for informing the scientist on the likelihood of success of the compound, while including the information of covariates for patient characteristics in the trial population for planning future pre-market or post-market trials. Copyright (c) 2014 John Wiley & Sons, Ltd.
引用
收藏
页码:249 / 264
页数:16
相关论文
共 22 条
[1]  
Agrestis A, 2013, CATEGORICAL DATA ANA
[2]  
[Anonymous], APPL STAT
[3]   Maximum likelihood methods for cure rate models with missing covariates [J].
Chen, MH ;
Ibrahim, JG .
BIOMETRICS, 2001, 57 (01) :43-52
[4]   Bayesian Design of Noninferiority Trials for Medical Devices Using Historical Data [J].
Chen, Ming-Hui ;
Ibrahim, Joseph G. ;
Lam, Peter ;
Yu, Alan ;
Zhang, Yuanye .
BIOMETRICS, 2011, 67 (03) :1163-1170
[5]   A new statistical decision rule for single-arm phase II oncology trials [J].
Chen, Yiyi ;
Chen, Zunqiu ;
Mori, Motomi .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2016, 25 (01) :118-132
[6]   Sample size and the probability of a successful trial [J].
Chuang-Stein, Christy .
PHARMACEUTICAL STATISTICS, 2006, 5 (04) :305-309
[7]   Bayesian predictive approach to interim monitoring in clinical trials [J].
Dmitrienko, A ;
Wang, MD .
STATISTICS IN MEDICINE, 2006, 25 (13) :2178-2195
[8]  
Eatons ML, 2012, BAYESIAN ANAL, V7, P771
[9]  
Fienbergs SE, 1979, SOCIOL METHODOL, P1
[10]   A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax [J].
Gilderman, Larry I. ;
Lawless, James F. ;
Nolen, Thomas M. ;
Sterling, Tina ;
Rutledge, Ruth Z. ;
Fernsler, Doreen A. ;
Azrolan, Neal ;
Sutradhar, Santosh C. ;
Wang, William W. ;
Chan, Ivan S. F. ;
Schlienger, Katia ;
Schodel, Florian ;
Silber, Jeffrey L. .
CLINICAL AND VACCINE IMMUNOLOGY, 2008, 15 (02) :314-319